Cell therapy developer Senti Biosciences' Q3 net loss narrows

Senti Biosciences Holdings

13/11/2025 21:43

Overview

Senti Biosciences Q3 net loss was $18.1 mln, with EPS of -$0.69

Cash and cash equivalents decreased to $12.2 mln from $48.3 mln at end of 2024

R&D expenses rose to $10.5 mln, driven by higher external services and personnel costs

Result Drivers

R&D EXPENSES - R&D expenses increased due to higher external services and personnel costs

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
-$0.69
Q3 Net Income
-$18.1 mln
Q3 Operating Expenses
$16.95 mln
Q3 Operating Income
-$16.95 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Senti Biosciences Inc is $12.00, about 84.2% above its November 12 closing price of $1.89

Press Release: ID:nGNX7Y1DH5

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)